Mirum Pharmaceuticals, Inc.
MIRM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001759425
In the last 90 days, Mirum Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 328 institutions reported holding it in 13F filings for Q2 2026, worth $8.36B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $6.08B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $9.80M in total
- 5
- 13F holdersQ2 2026, +17 vs. previous quarter
- 328
- 13F valueReported value at the end of Q2 2026
- $8.36B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $521.3M
- +54.7% year over year
- Net income, FY2025
- -$23.4M
- No comparable prior period
- Free cash flow, FY2025
- $54.9M
- +488.0% year over year
- Revenue, Q3 FY2026
- $185.7M
- +39.6% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $23.4M (4.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 6.66M
- Shares sold short
- Change
- −322.3K
- −4.6% vs. previous
- Days to cover
- 7.30
- At average daily volume
Superinvestors holding MIRM, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MIRM at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Mirum Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)8:46 PM ET | Nov 4 | Same day | Peetz ChristopherCHIEF EXECUTIVE OFFICER | SSale | −20.0K | $90.00 | −$1.80M | −8.8%206.6K after | 10b5-1 |
| Sep 15, 2026 (view filing)4:10 PM ET | Sep 14 | 1 day | Bjerkholt EricCHIEF FINANCIAL OFFICER | SSale | −9.94K | $98.37 | −$978.1K | −18.2%44.7K after | |
| Sep 3, 2026 (view filing)6:54 PM ET | Sep 2 | 1 day | Howe JolandaSVP, GLOBAL CONTROLLER | SSale | −658 | $100.00 | −$65.8K | −51.6%616 after | 10b5-1 |
| Sep 3, 2026 (view filing)6:52 PM ET | Sep 1 | 2 days | Peetz ChristopherCHIEF EXECUTIVE OFFICER | SSale | −30.0K | $98.68 | −$2.96M | −13.4%194.4K after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)6:19 PM ET | Aug 18 | 1 day | Howe JolandaSVP, GLOBAL CONTROLLER | SSale | −40.0K | $100.00 | −$4.00M | −96.9%1.27K after | |
| Aug 12, 2026 (view filing)5:14 PM ET | Aug 11 | 1 day | Bjerkholt EricCHIEF FINANCIAL OFFICER | SSale | −6.00K | $99.90 | −$599.5K | −14.2%36.4K after | 10b5-1 |
| Aug 11, 2026 (view filing)5:41 PM ET | Aug 10 | 1 day | Peetz ChristopherCHIEF EXECUTIVE OFFICER | SSale | −20.0K | $98.92 | −$1.98M | −9.3%194.3K after | 3 lots10b5-1 |
| Aug 5, 2026 (view filing)4:26 PM ET | Aug 3 | 2 days | Howe JolandaSVP, GLOBAL CONTROLLER | SSale | −1.84K | $105.29 | −$193.7K | −59.1%1.27K after | 10b5-1 |
| Jul 8, 2026 (view filing)5:12 PM ET | Jul 6 | 2 days | Peetz ChristopherCHIEF EXECUTIVE OFFICER | SSale | −20.0K | $122.27 | −$2.45M | −9.3%194.3K after | 4 lots10b5-1 |
| Jul 8, 2026 (view filing)5:07 PM ET | Jul 6 | 2 days | Bjerkholt EricCHIEF FINANCIAL OFFICER | SSale | −5.00K | $122.25 | −$611.3K | −10.6%42.2K after | 4 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 328 holdersThe largest institutional positions in Mirum Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7,679,684 | $899.1M | 19.58% | 00.0% | Unchanged |
| Jupiter Topco LLC | 5,909,184 | $691.7M | 0.28% | +5,909,184 | New |
| BlackRock, Inc. | 4,390,063 | $513.9M | 0.01% | +543,533+14.1% | Added |
| FMR LLC | 3,670,314 | $429.7M | 0.02% | +1,704,939+86.7% | Added |
| Price T Rowe Associates Inc | 2,655,607 | $310.9M | 0.03% | +938,186+54.6% | Added |
| Vanguard Portfolio Management LLC | 2,377,019 | $278.3M | 0.01% | +944,936+66.0% | Added |
| Vanguard Capital Management LLC | 2,254,109 | $263.9M | 0.01% | −160,667−6.7% | Reduced |
| State Street Corp | 2,170,689 | $254.1M | 0.01% | +226,408+11.6% | Added |
| William Blair Investment Management, LLC | 1,404,741 | $164.5M | 0.49% | +1,069,072+318.5% | Added |
| Geode Capital Management, LLC | 1,393,908 | $163.2M | 0.01% | +133,905+10.6% | Added |
Holders of 5% or more of MIRM
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Mirum Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G/A | 14.30%22.7M shares | +3.30 ppfrom 11.00% | Jul 10, 20244 filings | May 14, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 9.70%5.91M shares | −2.10 ppfrom 11.80% | Feb 14, 20259 filings | Aug 13, 2026 | SEC |
| Frazier Life Sciences IX, L.P. | 13D/A | 6.80%4.11M shares | −0.80 ppfrom 7.60% | Aug 16, 20226 filings | Jan 27, 2026 | SEC |
| FMR LLC | 13G | 6.20%3.78M shares | New | Aug 6, 20261 filing | Aug 6, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 5.70%3.47M shares | – | Oct 22, 20243 filings | Apr 27, 2026 | SEC |